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Traditional Chinese medicines (TCM), or as part of so‑called 
“complementary and alternative medicines” (CAM) by Western 
medical communities, are being increasingly recognized and used 
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ABSTRACT
Adjuvants can be used to enhance the immunogenicity of antigens and improve the efficacy of vaccines. Potent adjuvant action is known 
to often correlate with the activation of the transcription factor, nuclear factor‑κB (NF‑κB). Specific plant polysaccharides and a variety of 
phytochemicals from foods and traditional medicinal herbs have been shown to modulate NF‑κB activation. In the present study, selected 
plant polysaccharides and phytochemicals were evaluated for use as a DNA vaccine adjuvant in a murine melanoma model. We observed 
that a specific ethanol extract fraction (DsCE‑I) from the tuber of a key Traditional Chinese Medicine plant, Dioscorea (山藥 Shān Yào), 
enhanced the protection against melanoma after immunization with a gene‑based vaccine. A number of anti‑inflammatory phytochemicals 
tested were able to partially diminish the inflammation‑associated tumorigenesis elicited by LPS. Among the several phytochemical 
combinations investigated, the use of an adjuvant containing LPS in combination with emodin resulted in smaller tumors and higher survival 
rate in test mice than the use of other adjuvant treatments and the control sets in this DNA cancer vaccine model. A Dioscorea polysaccharide 
fraction (DsCE‑I) and several specific phytochemicals warrant further exploration as useful adjuvants for anticancer vaccines.
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in public health care throughout the world. Government‑ and 
industry‑funded research and development have started to focus 
on the use of scientific evidence‑based approaches to verify the 
traditionally claimed medicinal efficacies, specific bioactivities, 
and related pharmacological mechanisms of such remedies. In 
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Asia, Dioscorea spp. (山藥 Shān Yào) are very popularly used 
as a health food/supplement and/or as a TCM herb that can be 
taken alone or in multiple‑herb formulations. They are used for 
a broad range of ailments or health care measures. Some specific 
biological effects have been reported for Dioscorea spp., including 
antitumor,[1] induction of hypoglycemia in experimental mice and 
rabbits,[2,3] antibacterial,[4] as well as antioxidative and hypolip‑
idemic activities.[5] Anecdotal evidences suggest that Dioscorea 
tubers taken as a food supplement may promote human health by 
regulating and upgrading the immune responses[6] and promoting 
antitumor activities;[1] however, credible experimental results and 
related mechanisms are still very limited.
Suppression of tumor progression by functional bioactivities 
of secondary metabolites from plants has been shown to confer 
anticancer or chemoprevention activities. Previously, we reported 
that co‑treatment with a 50‑75% ethanol‑partitioned fraction of 
the tuber crude extract of Dioscorea batatas (DsCE‑II) and inter‑
leukin‑2 (IL‑2) resulted in a significantly higher rate of murine 
splenocyte cell proliferation ex vivo than treatment with DsCE‑II 
or IL‑2 alone. This DsCE‑II fraction, which contains a polysac‑
charide with a high proportion of b‑1,4 linkage mannose (≥64%), 
also promoted the regeneration of specific progenitor cell popula‑
tions in damaged bone marrow tissues of 5‑fluorouracil–treated 
mice.[7] In addition, DsCE‑I, a 50% ethanol‑insoluble fraction 
of D. batatas, significantly increased granulocyte‑macrophage 
colony stimulating factor (GM‑CSF) promoter activity in normal 
and inflamed skin,[8] suggesting that DsCE‑I may be useful as an 
adjuvant for use alongside chemotherapy in cancer.
Potent adjuvant action often correlates with nuclear 
factor‑κB (NF‑κB) activation, as exemplified by monophosphoryl 
lipid A (MPL).[9] However, NF‑κB activation is also known to 
play an important role in the development and/or maintenance of 
various types of cancer. NF‑κB has been linked to cell proliferation, 
invasion, angiogenesis, metastasis, suppression of apoptosis, and 
chemoresistance in multiple tumor systems.[10,11] Most carcinogens, 
inflammatory agents, and tumor promoters, including tar components 
from cigarette smoking, phorbol ester, okadaic acid, H2O2, and tu‑
mor necrosis factor‑alpha (TNF‑α), have all been shown to activate 
NF‑κB. In addition, NF‑κB has been shown to regulate the expression 
of a number of genes whose products are involved in tumorigenesis. 
Therefore, the balance of NF‑κB in anticancer immune responses 
and tumorigenesis is a critical and tricky issue in cancer therapy.
The present study investigated the adjuvant effect of DsCE‑I 
in protecting against B16‑hgp100 melanoma in a DNA vaccine 
model. In addition, several anti‑inflammatory phytochemicals 
known for their anti–NF‑κB activity were investigated for their 
ability to diminish the inflammation‑associated tumorigenesis in 
this vaccine model study.
MATERIALS AND METHODS
Preparation of Dioscorea plant tuber crude extract (DsCE‑I) 
using ethanol partition
Tuber tissues of the Dioscorea plant, D. batatas Dec‑
ne (山藥 Shān Yào), were used to prepare the ethanol ex‑
tract DsCE‑I. The authenticity of all plant materials and 
species verification was validated by Dr. Sin‑Yie Liu, Taiwan Ag‑
ricultural Research Institute. Cultivation, growth, taxonomy, and 
agricultural practice details have been previously reported.[12] The 
preparation of DsCE‑I was conducted as described previously.[8] 
In brief, 10 g tuber powder was mixed with 100 ml Milli‑Q water, 
stirred for 1 h at room temperature, and centrifuged at 24,000 g for 
20 min at 4°C. The supernatant was filtered through glass wool. 
The pellet was resuspended with another 100 ml water, stirred, 
centrifuged, and re‑extracted as above. The supernatants from two 
extractions were then pooled to yield a crude extract (CE) fraction. 
The CE fraction was further extracted stepwise with 50% (V/V) 
ethanol. The ethanol‑insoluble fractions were collected by centrifu‑
gation at 24,000 g for 20 min at 4°C; the pellet was lyophilized 
and then dissolved in sterilized water at 10 mg/ml. The fractions 
were named DsCE‑I. Limulus amoebocyte lysate (LAL) assays (as‑
sociates of Cape Cod, Falmouth, MA, USA) were performed to 
detect possible endotoxin contamination.
Reagents
Pyrrolidine dithiocarbamate (PDTC), SB203580, Lipopoly‑
saccharide (LPS, Escherichia coli 055:B5), polymyxin B, for‑
skolin, friedelin, oleanolic acid, resveratrol, and nidosamide were 
purchased from Sigma‑Aldrich (St. Louis, MO, USA). Emodin 
was purchased from ACROS Organics (Fair Lawn, NJ, USA). 
Liquiritigenin was purchased from Extrasynthese (Lyon, France). 
Honokiol was purchased from Pharmaceutical Industry Technol‑
ogy Development Center (New Taipei City, Taiwan).
Mice
Female C57BL/6JNarl mice (6‑8 weeks old), which were 
purchased from the National Laboratory Animal Breeding and 
Research Center, Taipei, Taiwan, were maintained under stan‑
dard pathogen‑free conditions. All facilities were approved by 
the Academia Sinica Institutional Animal Care and Utilization 
Committee (IACUC), and all animal experiments were conducted 
under the institutional guidelines established by the Animal Core 
Facility and IACUC in Academia Sinica, Taipei, Taiwan.
Cell lines and construction of cDNA expression vectors, 
stable gene transfection, and transgene studies
The mouse B16F10 (B16) melanoma cell line was obtained 
from American Type Culture Collection (ATCC; Manassas, VA, 
USA). B16 cells stably transfected with hgp100 cDNA vector, des‑
ignated as B16‑hgp100, were obtained as reported previously.[13] 
pNiFty‑secreted embryonic alkaline phosphatase (SEAP) plasmid 
was purchased from InvivoGen (San Diego, CA, USA). The 
hgp100 cDNA expression plasmid pWRG1644 was constructed 
as reported previously.[14]
Transfection and SEAP reporter assay
B16‑hgp100 melanoma cells were grown in Roswell Park 
Memorial Institute (RPMI) medium supplemented with 10% fetal 
bovine serum (FBS), 2 mM l‑glutamine, 100 U/ml penicillin, and 
100 μg/ml streptomycin at 37°C in a humidified 5% CO2/95% air 
incubator. The cells were seeded as 2 × 104 cells/well in a 96‑well 
plate. After 24 h, B16‑hgp100 melanoma cells were transfected 
with pNiFty‑SEAP plasmid in the presence of lipofectin for 24 h. 
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The transfected cells were then incubated with DsCE‑I for 24 h 
and the supernatants were collected for chemiluminescent SEAP 
reporter gene assay. Chemiluminescent reporter gene assay was 
conducted by Phospha‑Light™ system (AB Applied Biosystems, 
Bedford, MA, USA).
Sugar composition and sugar linkage analysis
Sugar composition determined by gas chromatography mass 
spectroscopy (GC‑MS) has been described in an earlier report.[15] 
Hakomori methylation analysis used to examine carbohydrate 
linkage has also been clearly described in an earlier report.[16]
Gene‑based immunization and challenge of mice with tumor 
cells
Skin of C57BL/6JNarl mice (5 mice/group) was transfected 
at two sites with hgp100 DNA (2.5 mg/mouse) using a Bio‑Rad 
Helios gene gun delivery system as described previously.[13] Seven 
days later (day 0), vaccinated mice were challenged intrader‑
mally (i.d.) with 5 × 104 B16‑hgp100 cells and were administered 
DsCE‑I subcutaneously. Transfected mice were examined twice 
weekly for tumor appearance, and tumor volumes were determined 
form the length and width of test tumors; survival time of mice 
was also observed.
Statistical analysis
Statistical analyses were carried out with STATGRAPHICS 
Plus version 3.0 (Statistical Graphics Corp., Princeton, NJ, USA). 
Groups were compared by one‑way analysis of variance (ANOVA). 
P values less then 0.05 were considered statistically significant.
RESULTS
DsCE‑I confers efficacious adjuvant activity on suppression 
of melanoma mediated by hgp100 DNA vaccination
GM‑CSF is an important hematopoietic growth factor and 
a multi‑functional immune modulator. It has been extensively 
studied for use as an adjuvant in various cancer vaccine ap‑
proaches. Our previous study showed that DsCE‑I can significantly 
increase GM‑CSF promoter activity in normal and inflamed skin.[8] 
Hence, we assessed the adjuvant effect of DsCE‑I on protection 
against B16‑hgp100 melanoma. The skin tissue of each mouse was 
transfected at two abdominal sites with hgp100‑encoding plasmid 
DNA, by using a gene gun–mediated transgene delivery. Different 
concentrations of DsCE‑I were emulsified in incomplete Freund’s 
adjuvant (IFA) and then subcutaneously injected into test mice. 
One week later (Day 0), vaccinated mice (N = 9) were challenged 
i.d. with 5 × 104 B16‑hgp100 cells. At Day 15 after tumor chal‑
lenge, tumor size and survival time of the unvaccinated or vac‑
cinated mice were measured. As seen in Figure 1a, in comparison 
with mice receiving a high dose of DsCE‑I (i.e. 100 μg/mouse) 
treatment, mice receiving a low dose of DsCE‑I (1 μg/mouse) 
treatment showed significantly smaller tumor sizes (P < 0.05, as 
compared to the treatment with a medium or high dose of DsCE‑I). 
Furthermore, as shown in Figure 1b, survival time of the vaccinated 
mice was considerably longer than that of the control mice. Results 
from mice tested with a medium dose (10 μg/mouse) showed a 
level of tumor burden and mouse survival time in between that 
of the high and low DsCE‑I doses tested [Figure 1a and b]. These 
results together demonstrated that the low dose of DsCE‑I tested 
(1 μg/mouse) effectively protected vaccinated mice from the tumor 
burden of B16‑hgp100 melanoma.
Characterization of the chemical composition of DsCE‑I
Since DsCE‑I can exhibit potent immunomodulatory ac‑
tivities, we characterized the chemical content of DsCE‑I by gel 
filtration and GC‑MS analysis. As shown in Figure 2, symmetri‑
cal peaks exhibiting a relatively high absorbance in refractive 
index (RI) detector as well as at UV280 in size exclusion column 
were obtained for DsCE‑I, prepared and presented as a watery, 
non‑viscous aqueous extract. Based on the sugar composition 
and linkage analysis, a high content of glucose polymer (≥71%) 
Figure 1. Effect of DsCE‑I dosage on hgp100 gene‑based vaccination, measured as protection against B16‑hgp100 melanoma. Abdominal skin of 
C57BL/6 mice was transfected at two tissue sites with hgp100 cDNA expression plasmid pWRG1644 (2.5 mg/mouse) using a Helios gene gun. Seven 
days later (Day 0), the vaccinated mice were challenged i.d. with 5 × 104 B16‑hgp100 cells and administered DsCE‑I subcutaneously at the indicated 
concentrations. Tumor size (in diameter) on Day 15 (a) and the percentage of survival for test mice that developed tumors (b) are indicated. (a: No 
vaccination, b: hgp100, c: hgp100 + 100 μg/mouse DsCE‑I, d: hgp100 + 10 μg/mouse DsCE‑I, e: hgp100 + 1 μg/mouse DsCE‑I)
ba
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with b‑1,4 linkage was detected in DsCE‑I [Table 1], as we have 
previously reported.[7]
Effect of DsCE‑I on NF‑κB activation in B16‑hgp100 
melanoma
To investigate the possible effect of DsCE‑I on NF‑kB activa‑
tion in tumor cells, the activity of transgenic NF‑κB–inducible 
endothelial‑leukocyte adhesion molecule 1 (ELAM‑1) composite 
promoter was examined in B16‑hgp100 melanoma. B16‑hgp100 
melanoma cells were first tranfected with NF‑κB–inducible re‑
porter plasmid pNiFty‑SEAP in the presence of lipofectin for 24 h. 
The transfected cells were then incubated with DsCE‑I for 24 h 
and chemiluminescent reporter gene assays were conducted. LPS 
is known to be a strong stimulator for activation of NF‑κB and 
mitogen‑activated protein kinases (MAPKs). Therefore, LPS was 
used as a positive control and the corresponding luciferase activity 
was normalized as 100%. To illustrate the specificity, the effects of 
inhibitors of the LPS‑induced activation were also examined. The 
results showed that DsCE‑I stimulated the transgenic composite 
promoter activity of NF‑κB–inducible ELAM‑1 in B16‑hgp100 
melanoma cells. As seen in Figure 3, DsCE‑I effectively induced 
NF‑κB activation, and this activity was significantly suppressed 
by SB203580 (a known inhibitor of MAPK p38) and PDTC (a 
known inhibitor of NF‑κB) (P < 0.001, as compared to DsCE‑I 
only treatment). These results indicate that the immunomodula‑
tory effect of DsCE‑I may be via the p38 and NF‑κB cascade 
signaling pathways. Furthermore, polymyxin B was able to inhibit 
LPS‑induced activation completely, but it only partially inhibited 
DsCE‑I–induced NF‑κB activation, suggesting that the NF‑κB 
activation of DsCE‑I was not likely mediated via toll‑like receptor 
4 (TLR4) receptor binding.
NF‑κB inhibitors can diminish inflammation‑associated 
tumorigenesis elicited by DsCE‑I or LPS
DsCE‑I enhanced protection against B16‑hgp100 melanoma 
in a DNA vaccine model. However, higher doses of DsCE‑I did 
not result in more protection, but instead resulted in less protec‑
tion. In addition, our results also showed that DsCE‑I effectively 
stimulated NF‑κB activation in B16‑hgp100 melanoma cells. 
These results imply that DsCE‑I–induced NF‑κB activation in 
B16‑hgp100 cells may impair the adjuvant effect on protection 
against B16‑hgp100 melanoma in test DNA vaccine model. To 
further investigate this possibility, we performed an experiment 
using NF‑κB inhibitors to determine whether inhibition of NF‑κB 
activation could result in enhancement of the adjuvant effect 
of DsCE‑I or LPS on vaccine protection against B16‑hgp100 
melanoma. The skin tissues of each mouse were transfected 
at two abdominal sites with hgp100‑encoding plasmid DNA, 
delivered via gene gun. Test mice were then administered sub‑
cutaneously with DsCE‑I or LPS emulsified in IFA. One week 
later (Day 0), the vaccinated mice were challenged i.d. with 
5 × 104 B16‑hgp100 cells. After the tumor challenge, survival 
time of the mice was recorded. At Day 15 after the tumor chal‑
lenge, tumor size and mouse survival rate of the test mice were 
measured. Figure 4a and b shows that treatments with NF‑κB 
inhibitors combined with DsCE‑I or LPS prolonged the sur‑
vival of test mice and led to tumor regression, suggesting that 
a balanced activation level of NF‑κB is very important for the 
progression of tumorigenesis and the gene‑based vaccination 
against test melanoma tumor.
Specific anti‑inflammatory phytochemicals can diminish 
inflammation‑associated tumorigenesis elicited by LPS
We showed that inhibition of NF‑κB activation can enhance 
the regression of melanoma induced by hgp100 DNA vaccine 
accompanied by treatment with DsCE‑I or LPS. We next tested 
whether a group of anti‑inflammatory phytochemicals that are 
known to confer anti–NF‑κB activity may be useful as anticancer 
adjuvants in the current DNA vaccine model. The skin tissues 
Figure 2. TSK HW‑55F gel filtration and profile analysis of polysaccharides 
of DsCE‑I fraction from D. batatas. Figure 2 is adapted from eCAM doi: 
10.1093/ecam/neq032
Figure 3. Effect of inhibitors on LPS and DsCE‑I induced NF‑κB 
activation in B‑16 cells. Data are represented as the mean ± SD. (a: 
0.1 μg/ml LPS, b: 0.1 μg/ml LPS + 15 μM SB203580, c: 0.1 μg/ml LPS 
+ 30 μM PDTC, d: 0.1 μg/ml LPS + 400 units polymyxin B, e: 100 μg/ml 
DsCE‑I, f: 100 μg/ml DsCE‑I + 15 μM SB203580, g: 100 μg/ml DsCE‑I + 
30 μM PDTC, h: 100 μg/ml DsCE‑I + 15 μM SB203580 + 30 μM PDTC, 
i: 100 μg/ml DsCE‑I + 400 units polymyxin B, j: control)
D E F G H I J K L M7UHDWPHQWSS5HODWLYH1)N%DFWLYLW\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Table 1. GC‑MS sugar linkage analysis of DsCE‑I polysaccharides 
extracted from D. batatas
Sugar residue Ara Rha Fuc Xyl Man Gal Glc
Percentage of 
DsCE‑I carbohydrate
1.1 0.7 0.2 0.8 11.4 14.7 71.1
Ara: Arabinose; Rha: Rhamnose; Fuc: Fucose; Xyl: Xylose; Man: Mannose; 
Gal: Galactose; Glc: Glucose. Table 1 is adapted from eCAM doi: 10.1093/
ecam/neq032
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of test mice were gene gun–transfected at two abdominal sites 
with hgp100‑encoding plasmid DNA. LPS combined with test 
phytochemicals were emulsified in IFA and then subcutaneously 
injected into test mice. One week later (Day 0), the vaccinated 
mice were challenged i.d. with 5 × 104 B16‑hgp100 cells. Our 
results showed that adjuvants containing LPS in combination with 
emodin had conferred the highest anti–NF‑κB activity among all 
the tested phytochemicals (data not shown), and it also resulted in a 
much smaller tumor size (P < 0.05, as compared to hgp100 + LPS 
treatment) and significantly higher survival rate than the other 
tested adjuvant treatments and control in the melanoma DNA 
vaccine model [Figure 5a and 5b]. Hence, emodin has stood out 
as the utmost effective one amongst all tested phytochemicals for 
potential application as adjuvant for gene‑based cancer vaccines 
in this comparative assay.
DISCUSSION
Various Traditional Chinese herbal medicinal literatures, such 
as the Ben Cao Gang Mu (本草綱目 Běn Cǎo Gāng Mù)[6] recog‑
nized as a classical TCM pharmacopoeia, have repeatedly related 
the various homeostatic, health care, and immune‑regulatory 
effects to Dioscorea (山藥 Shān Yào) tuber. It is widely used 
as a functional food and/or phytomedicine in a number of East 
Asian cultures.[7] It is often served either as a fresh vegetable 
or in the form of stewed tubers in tonic soups. D. batatus tuber 
Figure 4. Effect of NF‑kB inhibitors on B16‑hgp100 melanoma in DNA vaccine model. C57BL/6 mice were skin vaccinated by transfection with 
hgp100 DNA (2.5 mg/mouse) using a gene gun. NF‑kB inhibitors were administered subcutaneously. Seven days later (Day 0), the vaccinated mice 
were challenged i.d. with 5 × 104 B16‑gp100 cells. Tumor size (in diameter) (a) and the percent survival of test mice that developed tumors (b) 
were serially measured. (a: No vaccination, b: hgp100, c: hgp100 + 100 μg/mouse DsCE‑I, d: hgp100 + 100 μg/mouse DsCE‑I + PDTC, e: 
hgp100 + 100 μg/mouse DsCE‑I + PDTC + SB203580, f: hgp100 + 1 μg/mouse LPS, g: hgp100 + 1 μg/mouse LPS + PDTC, h: hgp100 + 1 μg/mouse 
LPS + SB203580, i: hgp100 + 1 μg/mouse LPS + PDTC + SB203580)
ba
Figure 5. Effect of anti‑inflammatory phytochemicals as vaccine adjuvant against B16‑hgp100 melanoma cells in a DNA vaccine model. Skin of 
C57BL/6 mice was transfected with transgenic hgp100 cDNA (2.5 mg/mouse) using a gene gun. Anti‑inflammatory phytochemicals in combination with 
LPS were then administered subcutaneously. Seven days later (Day 0), the vaccinated mice were challenged i.d. with 5 × 104 B16‑gp100 cells. Tumor 
size (in diameter) (a) and the percent survival of test mice that developed tumors (b) were serially measured. (a: No vaccination, b: hgp100 + LPS, 
c: hgp100 + LPS + emodin, d: hgp100 + LPS + liquiritigenin, e: hgp100 + LPS + honokiol, f: hgp100 + LPS + forskolin, g: hgp100 + LPS + friedelin, 
h: hgp100 + LPS + oleanolic acid, i: hgp100 + LPS + resveratrol, j: hgp100 + LPS + niclosamide)
ba
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slices are also popularly used as a key component in many TCM 
formulations.[7] Hence, we investigated here one of the essential 
components of D. batatas Decne, DsCE‑I, in terms of its effect 
on specific immunomodulatory activities. We have previously 
reported the isolation of two different ethanol fractions, DsCE‑I 
and DsCE‑II.[7] We not only have characterized their chemical 
contents but also distinguished their very different (even opposite) 
immunomodulatory activities for different and specific potential 
clinical applications. Therefore, our previous[7,8] and present studies 
may help strengthen the knowledge‑based understanding on the 
historical claims of D. batatas Decne.
Gene‑based (e.g. DNA) vaccines have been shown to not only 
induce antigen‑specific CD8+ T lymphocytes but also activate 
CD4+ T cells for antitumor immunities.[14] However, for many 
cases, the efficacy of DNA vaccines is still limited and they 
need technical improvement. Therefore, a good combination of 
antigen‑specific DNA vaccines with a potent adjuvant (s) has 
been considered as an important strategy for immunotherapy or 
therapeutic vaccination against cancers. GM‑CSF has been ex‑
tensively studied for use as an adjuvant in various cancer vaccine 
approaches.[17‑19] It can not only can increase specific immune 
responses[20] but also alter the balance of Th1/Th2 cytokines.[21] In 
addition, recent studies also demonstrated a novel role for GM‑CSF 
in enhancing the expansion and survival of Th17 cells via the 
regulation of IL‑6 and IL‑23 in vivo.[22] Since we demonstrated 
recently that DsCE‑I can significantly increase the transgenic 
GM‑CSF promoter activity in vivo,[8] we hypothesized in this study 
that DsCE‑I may also be employed as an adjuvant when combined 
with hgp100 DNA vaccine in fighting against B16‑hgp100 mela‑
noma. In this study, we showed that lower dosages (e.g. 1 μg/ml) 
of DsCE‑I administered along with hgp100 DNA vaccine can 
effectively suppress test melanoma tumor growth and enhance 
mouse survival rate. However, this antitumor effect of DsCE‑I is 
decreased when applied at 10‑100 (higher) doses. Compared to 
control treatment (hgp100 DNA only), our data showed that at the 
higher test dosage (100 μg/ml), DsCE‑I has no effect on the sup‑
pression of melanoma growth. Hence, this result led us to further 
characterize the chemical composition and feature of DsCE‑I.
Our result showed that polysaccharides constitute a major 
part (≥71%) of DsCE‑I, with a b‑1,4 linkage of the glucose 
polymer [Table 1]. Some b‑glucans are known to confer potent 
immunomodulatory activity with an effect on both innate and 
adaptive immunities.[23] Some of these activities were considered 
to correlate with NF‑κB activation and signaling.[24] However, 
growing evidences are also suggesting that constitutive NF‑κB 
activation is closely correlated to human malignancies.[10,11] Hence, 
we investigated the possibility if at high dosage (e.g. 100 μg/dose), 
DsCE‑I can drastically induce NF‑kB activation in test B16‑hgp100 
melanoma and result in enhanced tumor progression. This possibil‑
ity was demonstrated by the result that the high dosage of DsCE‑I 
indeed stimulated the transgenic composite promoter activity of 
NF‑κB–inducible ELAM‑1 in B16‑hgp100 melanoma cells. Our 
in vivo experiment conducted with NF‑κB inhibitors [Figure 4] 
further confirmed this hypothesis. Due to the above considerations, 
we further investigated whether specific anti‑inflammatory phyto‑
chemicals, abundant in a number of TCM herbs, were also able to 
partially diminish the inflammation‑associated tumorigenesis elic‑
ited by high dose of DsCE‑I or LPS. Our results shown in Figure 5 
demonstrate a test that adjuvant containing LPS in combination with 
emodin exhibited the highest antitumor effects, resulting in smaller 
tumor size and higher survival rate in test mice, than those from 
other adjuvant treatments and control mice in this melanoma DNA 
vaccine model. Our results correlate well with a previous finding 
in which a combination of DNA vaccination and treatment with 
epigallocatechin‑3‑gallate (EGCG) generated synergistic antitumor 
therapeutic effects that were more effective than a single therapy 
modality.[25] These results are also in agreement with studies that 
indicated the suppression of NF‑κB activities led to suppression of 
tumor growth and enhanced survival rate in treated animals. Pandey 
et al., reported that different dosages of berberine suppressed NF‑κB 
inhibitors and, thus, suppressed the growth of different carcinoma 
cells under in vitro conditions.[26] Curcumin has been shown to 
potentiate the antitumor effect of Bacillus calmette‑guerin against 
bladder cancer through the inhibition of NF‑κB and induction 
of TNF‑related apoptosis‑inducing ligand (TRAIL) receptors in 
bladder cancer cells.[27] In addition, previous studies also showed 
that emodin induced apoptosis in several types of cancer cells[28,29] 
and strongly inhibited tumor cell migration[30] and invasion.[31] 
Similarly, friedelin[32] and oleanolic acid[33] were also found to 
possess antitumor activity and suppress tumor growth. Therefore, 
we suggest that emodin as well as other anti‑inflammatory phyto‑
chemicals also could have the potential to serve as a useful adjuvant 
for (gene‑based) cancer vaccine approaches.
CONCLUSION
In conclusion, we present in this study evidence that low dos‑
ages of Dioscorea (山藥 Shān Yào) may be used as an adjuvant 
with DNA cancer vaccine, and it can suppress tumor growth and 
prolong survival in B16‑hgp100 melanoma‑challenged mice. In 
addition, some phytochemicals, especially emodin, followed by 
friedelin to a lesser extent, may also show good antitumor adju‑
vant activities when used alongside a DNA vaccination regimen. 
Further experimental studies are warranted to evaluate both the 
mechanisms of action and the potential clinical applications of 
these phytochemicals under in vitro and in vivo conditions.
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